Longeveron Inc.

LGVN Nasdaq SEC CIK 1721484
Follow Longeveron Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $115K −16.1% vs same quarter last year
Net income −$6.1M +15% vs same quarter last year
EPS, diluted −$1.91 +51.4% vs same quarter last year
Operating cash flow −$2.7M +46.8% vs same quarter last year
Revenue by quarter
$603K
$381K
$316K
$137K
$365K
$398K
$287K
$115K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1.2M−$22.7M
FY24$2.4M−$16M
FY23$709K−$21.4M
FY22$1.2M−$18.8M
FY21$1.3M−$17M
FY20$5.6M−$3.7M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2567%−1942.2%−1893.6%
FY2478.8%−690.7%−667.8%
FY2331.2%−2966%−3020.2%
FY2240.7%−1476.5%−1541.3%
FY2145.2%−1336.6%−1305.1%
FY2032.4%−67.1%−66.1%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$18.9M
FY24−$14.5M
FY23−$19.3M
FY22−$14.5M
FY21−$10M
FY20−$2.5M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Longeveron
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearLongeveronHealthcare median
FY25−1893.6%−30.6%
FY24−667.8%−47%
FY23−3020.2%−58%
FY22−1541.3%−80.4%
FY21−1305.1%−71.8%
FY20−66.1%−62.2%
FY19-−46.2%